In a significant step forward for next-generation immunotherapy, CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) has announced the allowance of two patent applications by the U.S. Patent and Trademark Office (USPTO). These approvals further strengthen the company’s intellectual property portfolio and advance its mission to revolutionize cancer treatment through engineered T cell technology.
🧬 What the New Patents Cover
The first allowance, Patent Application No. 17/040,472, titled “Cellular Immunotherapy Compositions and Uses Thereof,” provides coverage for both the composition and methods of use for CERo’s lead therapeutic candidate, CER-1236.
This patent secures protection for a combination of phosphatidylserine-targeting CD4+ CER-T cells alongside either CD8+ CAR-T cells or CD8+ recombinant TCR-T cells — a potentially powerful duo in the fight against cancer. The application was allowed on March 13, 2025, and is expected to formally issue as a U.S. patent pending final administrative steps.
The second allowance, Patent Application No. 17/040,317, focuses on the design elements of CER-1236.
Together, these new additions bring CERo’s total IP protection to 17 issued and allowed patents globally, covering 9 patent families and ensuring exclusivity through at least 2039 in the U.S.
🚀 Why This Matters
According to Chris Ehrlich, CEO of CERo Therapeutics:
This announcement comes on the heels of two major developments for CERo — the opening of its first clinical trial site for a Phase 1 trial in Acute Myeloid Leukemia (AML) and the FDA’s clearance of an Investigational New Drug (IND) application to begin human trials targeting ovarian and non-small cell lung cancers.
🧪 What Sets CERo Apart
CERo’s platform centers on what it calls Chimeric Engulfment Receptor T cells (CER-T) — a unique blend of adaptive and innate immune functionalities. Unlike traditional CAR-T cells, which rely on antigen recognition and activation, CER-T cells incorporate engulfment pathways that allow them to phagocytose and destroy cancer cells — mimicking a mechanism usually seen in innate immune cells.
This hybrid design could position CER-Ts as a more versatile alternative, with the potential to treat both blood cancers and solid tumors, a key limitation in current CAR-T therapies.
🧭 Looking Ahead
CERo is preparing to initiate clinical trials for CER-1236 in hematologic malignancies in 2025, and with its fortified patent portfolio, the company is well-positioned to push its immunotherapy pipeline forward — both scientifically and commercially.
The additional patent protections will not only support ongoing R&D and commercialization efforts but also provide a competitive moat in an increasingly crowded cell therapy space.
Conclusion:
As CERo advances toward clinical trials, these patent approvals reflect growing validation for its novel T cell engineering approach. With a focus on real innovation and strong IP protection, CERo Therapeutics continues to stake its claim as a leader in the evolving world of cellular immunotherapy.